Search the Newsreel

Enterprise value to revenue forward of Cytokinetics, Incorporated – BX:KK3A

This article displays the "Enterprise value to revenue forward" metric for Cytokinetics, Incorporated (BX:KK3A) on TradingView. It provides financial overview, documents, news, and community features related to the company. The page also includes various market data, tools, and community resources offered by TradingView.

Bronstein, Gewirtz & Grossman, LLC Is Investigating Cytokinetics, Incorporated (CYTK) And Encourages Shareholders to Connect

Bronstein, Gewirtz & Grossman, LLC has announced an investigation into Cytokinetics, Incorporated (NASDAQ: CYTK) regarding potential corporate wrongdoing. The firm is encouraging shareholders who purchased Cytokinetics securities before December 27, 2023, and still hold them, to contact them to assist with the investigation. Bronstein, …

CYTK|Cytokinetics Inc|Price:78.690|Chg%:+2.240

Cytokinetics Inc (CYTK) exhibits weak fundamentals but high growth potential, with its valuation considered fairly priced within the Biotechnology & Medical Research industry. Institutional ownership is very high, and analysts have consistently rated it as a "Buy" with a target price of $108.47. Despite …

Enterprise value to EBITDA forward of Cytokinetics, Incorporated – NASDAQ:CYTK

This article provides an overview of the "Enterprise value to EBITDA forward" metric for Cytokinetics, Incorporated (NASDAQ: CYTK) as listed on TradingView. It indicates that the data is sourced from ICE Data Services and FactSet, with SEC filings from Quartr. The content mainly consists …

Cytokinetics (CYTK) insider schedules 24,000-share option-related stock sale

Cytokinetics insider Andrew Callos has filed a Form 144 to sell 24,000 shares of common stock on July 30, 2026, connected to an exercise of stock options. The filing also details previous Rule 10b5-1 plan sales by Callos in May and June 2026, outlining …

The Bull Case For Cytokinetics (CYTK) Could Change Following UK NHS Backing Of Aficamten Access

Cytokinetics recently secured marketing authorization for MYQORZO (aficamten) in the UK to treat obstructive hypertrophic cardiomyopathy, with NICE recommending its use within the NHS. This approval, supported by Phase 3 trial data, is a significant step for the company, reinforcing its investment narrative around …

Andrew Callos of Cytokinetics Inc (CYTK) sells 14,000 shares after exercising options

Andrew Callos, EVP and Chief Commercial Officer of Cytokinetics Inc (CYTK), exercised 14,000 non-qualified stock options at $23.26 per share and subsequently sold all 14,000 shares at $79.88 per share under a Rule 10b5-1 trading plan. After these transactions, he holds 10,000 stock options …

Cytokinetics wins UK approval, NICE backing for heart disease drug

Cytokinetics' drug Myqorzo for obstructive hypertrophic cardiomyopathy (oHCM) has received approval from Britain's medicines regulator and a recommendation for NHS reimbursement from the National Institute for Health and Care Excellence (NICE). This will make the drug accessible to an estimated 6,600 patients in England …

Cytokinetics' cardiomyopathy drug cleared for NHS use

Cytokinetics' cardiac myosin inhibitor Myqorzo has received clearance for NHS use in the UK, making it a competitor to Bristol Myers Squibb's Camzyos. The drug is approved as an add-on treatment for adults with NYHA class II-III obstructive hypertrophic cardiomyopathy (HCM). This approval follows …

MHRA approves Cytokinetics’ aficamten for heart condition in UK

The UK's MHRA has granted marketing authorization for Cytokinetics' drug aficamten (MYQORZO) to treat symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adult patients. The National Institute for Health and Care Excellence (NICE) also recommended its use in England and Wales. This approval follows positive data …

Cytokinetics Secures MYQORZO Marketing Authorization in the UK

Cytokinetics has been granted marketing authorization for MYQORZO (aficamten) in the UK for treating symptomatic obstructive hypertrophic cardiomyopathy (oHCM). This approval, along with a positive recommendation from NICE, validates the drug's efficacy demonstrated in the SEQUOIA-HCM trial. While common adverse reactions include hypertension, palpitations, …

Cytokinetics Announces MHRA Marketing Authorisation for MYQORZO®▼ (aficamten) and Positive Guidance from NICE for Symptomatic Obstructive Hypertrophic Cardiomyopathy in England and Wales

Cytokinetics announced that the MHRA has granted marketing authorization for MYQORZO® (aficamten) across the UK for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in eligible adult patients. Simultaneously, NICE issued guidance recommending aficamten for use in eligible adult patients in England and Wales. …

Cytokinetics (CYTK) Expected to Release Earnings on Thursday

Wall Street expects a year-over-year decline in earnings on lower revenues when Cytokinetics (CYTK) reports results for the quarter ended June 2026. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock …

Cytokinetics (CYTK) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

CYTK4910847 Bond Profile — Key Metrics

This article provides a bond profile for CYTK4910847, issued by Cytokinetics, Inc. Key details include its 4.0% coupon rate, November 15, 2026 maturity date, and an outstanding amount of $8.63 million USD. Cytokinetics, Inc. is described as a biopharmaceutical company focused on developing treatments …

Cytokinetics president & CEO Robert Blum sells $606,525 in stock

Cytokinetics President and CEO Robert Blum sold common stock worth $606,525 on July 27, 2026, by disposing of 7,500 shares at $80.87 each. This sale occurred simultaneously with his acquisition of 7,500 shares via a non-qualified stock option exercise at a price of $10.60 …

Is Cytokinetics (CYTK) Cheap Or Has Its Cardiac Growth Story Already Been Priced In?

Cytokinetics (CYTK) has seen mixed short-term performance but strong 3-month and 1-year returns. Despite a "Most Popular Narrative" suggesting it's 23.7% undervalued with a fair value of $105.60, the company faces risks from ongoing losses, trial outcomes, and high expenses. Investors are encouraged to …

Cytokinetics Inc (CYTK) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Cytokinetics Inc (CYTK) focusing on its dividend and stock split history. It states that the company has distributed a total of $0.00 in dividends over the past five years, indicating no recent dividend payouts. The article also presents …

Cytokinetics, Incorporated Revenue Breakdown – BX:KK3A

Cytokinetics, Incorporated (BX:KK3A) reported a total revenue of 69.79 million CHF last year, primarily from its Muscle Activators and Muscle Inhibitors segment. This segment generated the entirety of the reported revenue, a significant increase from 16.78 million CHF in the previous year. The United …

CYTK|Cytokinetics Inc|Price:80.740|Chg%:-1.180

Cytokinetics Inc. (CYTK) is a late-stage cardiovascular biopharmaceutical company with strong fundamentals, high growth potential, and a 'Buy' rating from analysts, targeting $107.84. Despite a recent sideways stock performance, the company exhibits high revenue growth, substantial profit growth, and institutional ownership, though it shows …

Cytokinetics EVP Fady Malik sells $282,065 in company stock By Investing.com

Cytokinetics Executive Vice President of Research & Development, Fady Malik, sold 3,500 shares of company stock for $282,065 and simultaneously acquired 3,500 shares through stock options for $27,300. This follows the European launch of Cytokinetics' heart drug Myqorzo in Germany, with analysts like UBS …

Form 4 Cytokinetics Inc For: 24 July By Investing.com

This article from Investing.com is a regulatory filing update, specifically a Form 4 for Cytokinetics Inc, dated July 24. It provides a brief announcement of the filing without further details in the main text. The content also includes market data, news headlines, and advertising …

Insider Sell Alert: Fady Malik Sells 3,500 Shares of Cytokinetics Inc (CYTK)

Fady Malik, Executive Vice President of Research & Development at Cytokinetics Inc (CYTK), sold 3,500 shares of the company on July 21, 2026. This transaction follows a pattern of insider selling, with 77 insider sells and 0 insider buys over the past year. Cytokinetics …

Cytokinetics Insider Sold Shares Worth $282,065, According to a Recent SEC Filing

An insider at Cytokinetics, Incorporated (CYTK) recently sold shares valued at $282,065, according to a recent SEC filing. This transaction follows several other insider share sales reported in July and June, with values ranging from $266,390 to $1,287,000. Cytokinetics is a biopharmaceutical company focused …

Cytokinetics Will Share Q2 Results Aug. 6, Then Host Live Call

Cytokinetics (Nasdaq: CYTK) announced it will report its second-quarter 2026 financial results on August 6, 2026, at 4:00 PM Eastern Time. Following the announcement, senior management will host a conference call at 4:30 PM Eastern Time to discuss financial results and provide business updates. …

Cytokinetics, Incorporated (CYTK) Options Chain

This article provides the options chain data for Cytokinetics, Incorporated (CYTK), including both call and put options with various strike prices and expiration dates for January 21, 2028. It lists detailed information such as last trade date, strike price, last price, bid, ask, change, …

Cytokinetics to Announce Second Quarter Results on August 6, 2026

Cytokinetics, Incorporated (Nasdaq: CYTK) announced it will report its second-quarter 2026 financial results on August 6, 2026, at 4:00 PM Eastern Time. Following the announcement, senior management will host a conference call at 4:30 PM Eastern Time to discuss results and provide business updates, …

MYQORZO shows strong early sales and market expansion potential for Cytokinetics in HCM treatment.

Cytokinetics' drug MYQORZO is demonstrating strong commercial momentum with rapid market access and significant prescriber adoption, achieving over 30% new-to-brand share. Clinical trials suggest potential for earlier treatment use and expansion into non-obstructive hypertrophic cardiomyopathy, which could double its addressable market. While the company …

Cytokinetics CEO on the launch of its first commercial drug

Cytokinetics (CYTK) CEO Robert Blum joins Julie Hyman on Market Catalysts to discuss the company's first commercial product, Myqorzo, a treatment for a rare heart disease. Video Transcript 00:00 Speaker A Ours is a quintessential American innovation story. Sado kinetics just celebrated our 28th …

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Cytokinetics announced inducement grants to two new employees. These grants, comprising stock options to purchase 37,500 shares of common stock, were made as an inducement material to the employees entering into employment with Cytokinetics and were approved by the Compensation Committee of the company’s …

New Cytokinetics hires receive stock awards with 3- and 4-year vesting

Cytokinetics (Nasdaq: CYTK) announced that it granted inducement equity awards to 10 new employees on July 15, 2026, under Nasdaq Listing Rule 5635(c)(4). These awards include stock options for 21,220 shares with a 4-year vesting period and 14,067 restricted stock units (RSUs) with a …

Director stock grant at Cytokinetics (CYTK) highlights equity retainer

Cytokinetics director Wendell Wierenga was granted 75 shares of common stock on July 15, 2026, at $82.62 per share through the company’s Equity in lieu of Cash Retainer Program. These shares were fully vested upon grant, increasing his direct holdings to 35,563 shares. The …

Form 4 Cytokinetics Inc For: 16 July By Investing.com

This article announces the filing of Form 4 for Cytokinetics Inc. on July 16, 2026. Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) by company insiders when they trade shares of their own company's stock. …

Cytokinetics (CYTK) director Nancy Wysenski granted 75 fully vested shares

Cytokinetics (CYTK) director Nancy Wysenski was granted 75 shares of common stock as fully vested equity compensation on July 15, 2026, under the company's Equity in lieu of Cash Retainer Program. The shares were valued at $82.62 each, bringing her total direct holdings to …

Cytokinetics (CYTK) Could Be 22% Undervalued On Its Growth Narrative

Cytokinetics (CYTK) is considered 22% undervalued with a narrative fair value of $105.60, primarily due to the growing market for its therapies as the global population ages and the anticipated approvals of drugs like aficamten. Despite ongoing losses, recent insider activity and strong stock …

US23282WAC4 Bond Profile — Key Metrics

This article provides a detailed profile of the Cytokinetics, Incorporated 3.5% 01-JUL-2027 bond with the symbol US23282WAC4, traded on the Frankfurt Stock Exchange. Key metrics such as issue date, maturity date, outstanding amount, face value, and coupon rate are listed. The profile also includes …